EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD [Benzinga]
Tuesday, February 25, 2025 1 min read
Key Takeaway: Enveric Biosciences has obtained its first U.S. patent for the EVM401 Series, a new set of non-hallucinogenic compounds derived from mescaline. These compounds aim to treat conditions such as addiction and ADHD, providing potential new treatment options for patients with limited alternatives. This development marks a significant step in addressing neuropsychiatric disorders.
Price reaction · baseline $14.16 (2025-02-25T19:02:00.000Z) · hit during market hours · 2 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has secured a U.S. patent for EVM401 Series.
The compounds are non-hallucinogenic and derived from mescaline.
They target addiction, ADHD, and other neuropsychiatric disorders.
Potential to offer new therapeutic options for patients.
Full Press Release Details
Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other neuropsychiatric disorders, potentially offering new therapeutic avenues for patients who have limited options.
Full Article >>
Frequently Asked Questions
What is the EVM401 Series?
The EVM401 Series is a collection of non-hallucinogenic, mescaline-derived compounds.
What conditions do the EVM401 compounds target?
They are designed to address addiction, ADHD, anxiety, and other neuropsychiatric disorders.
What recent achievement did Enveric Biosciences accomplish?
Enveric Biosciences secured its first U.S. patent for the EVM401 Series.
Why are the EVM401 compounds significant?
They offer potential new therapeutic options for patients with limited treatment alternatives.